博腾股份 (300363)

Porton Pharma Solutions Ltd.

ASZ

Tags

Contract Research Organization (CXO)ImmunotherapyInnovative DrugsMedical ServicesGuozheng Value IndexGuozheng Growth IndexSmall Cap ValueSmall Cap GrowthEmerging Markets IndexOverseas BusinessEquity TransferChiNext 200 IndexChiNext InnovationChiNext 50 IndexChiNext IndexChiNext HealthcareChiNext TechShenzhen ConnectSZSE 300 IndexSZSE Value IndexSZSE Growth IndexPharma & BiotechSZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexChiNext Equal Weight IndexCS High Dividend Yield IndexCSI All-share Pharmaceutical Sector IndexSZSE 700 IndexSZSE Emerging Industries IndexSSE 700 Growth IndexZhongchuang Growth IndexSZSE 1000 IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCNI 1000 IndexBiomedicine IndexCSI Medical IndexExcellent Performance Strategy IndexGrowth 40 IndexCS Precision Medicine IndexZhongchuang Value IndexNew Virus PreventionJuly 2022 Lock-up ExpiryHuijin ConceptSeptember 2021 Lock-up ExpiryJune 2022 Lock-up ExpiryJune 2021 Lock-up ExpirySmall-cap High Beta IndexCS High-end Manufacturing IndexSME Board Innovation IndexChiNext Quality IndexSHS Innovative Drugs IndexSZSE High Beta IndexSZSE ChiNext 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexJuchao Small-cap IndexCCTV 500 IndexChiNext Basic IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexCSI All-share Pharmaceutical IndexSZSE Pharmaceutical 50 IndexSZSE 300 Equal Weight IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexInnovative Drugs 30 IndexCSI 700 IndexMid-small Cap IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang High Beta IndexSZSE 200 Return IndexSZSE 200 IndexYangtze River 100 IndexChiNext High Beta IndexZhongchuang 400 IndexCS Innovative Drugs IndexChiNext Growth IndexESG 300 IndexOrient Securities Competition IndexChiNext Return IndexCSI 1000 Value IndexSZSE 500 IndexChiNext Emerging IndexCSI 500 ESG IndexChongqing

K-Line Chart

No K-line data available

Company NameChongqing Porton Pharmaceutical Technology Co., Ltd.
Listing Date2014-01-29
Issue Price25.1RMB
Registered Capital54344.217610k RMB
Legal RepresentativeJu Nianfeng
Registered AddressFine Chemical Zone 1, Chongqing (Changshou) Chemical Industry Park
IndustryMedical Services
Main BusinessProvides pharmaceutical custom research and manufacturing services for multinational pharmaceutical companies and biotechnology companies in accordance with international standards. The main products are intermediates for innovative drugs.
Company ProfileChongqing Porton Pharmaceutical Technology Co., Ltd. (Stock Abbreviation: Porton Pharma, Stock Code: 300363) was established in July 2005. It is a leading domestic Contract Development and Manufacturing Organization (CDMO), primarily dedicated to providing custom research and manufacturing services for pharmaceutical intermediates and active pharmaceutical ingredients (APIs) required throughout the entire drug lifecycle from early clinical research to market launch for global pharmaceutical companies and new drug R&D institutions. It is a national high-tech enterprise. We have operations and branches in China (Chongqing, Chengdu, Shanghai, Jiangxi, Hong Kong), the United States, Belgium, Switzerland, and the United Kingdom, with over 1,600 employees globally. The company is committed to building a world-leading pharmaceutical service platform to bring new drugs to more patients faster. Through over a decade of experience in the CDMO field, we have developed core capabilities in providing pharmaceutical intermediates and APIs for international innovative drugs, from laboratory-scale, pilot-scale to commercial-scale production, along with a solid record of certifications and deliveries. The company's core production bases have successively passed on-site inspections by China's CFDA, the U.S. FDA, and Japan's PMDA.

Stock Details

1. Key Indicators

  • Total Shares(W): 54344.22
  • Circulating A-Shares(W): 49885.64
  • Earnings Per Share(RMB): 0.1500
  • Net Assets Per Share(RMB): 9.7803
  • Operating Revenue(W RMB): 254442.50
  • Total Profit(W RMB): 6216.20
  • Net Profit Attributable to Parent(W RMB): 7991.54
  • Net Profit Growth Rate(%): 138.71
  • Weighted Return on Equity(%): 1.5200
  • Operating Cash Flow Per Share(RMB): 0.6880
  • Undistributed Profit Per Share(RMB): 4.6736
  • Capital Reserve Per Share(RMB): 3.7419

2. Main Business

The main business covers:

  • Small molecule API business
  • Small molecule preparation business
  • Gene and cell therapy business
  • New molecule business

3. Company Basic Information

  • Company Name: Porton Pharma Solutions Ltd.
  • Listing Date: 2014-01-29
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 7 Yuntu Road, Beibei District, Chongqing, China
  • Website: www.portonpharma.com
  • Company Profile: The issuer was established by the overall change of Chongqing Porton Fine Chemicals Co., Ltd. into a joint stock company. On November 27, 2009, with the unanimous consent of all sponsors at the inaugural meeting and the first shareholders' meeting, based on the audited net assets of Porton Limited of RMB 89,959,142.75 as of September 30, 2009, RMB 70,000,000 was converted into 70,000,000 shares at a 1:1 ratio, and the balance of RMB 19,959,142.75 was recorded as capital reserve. On December 16, 2009, the issuer completed the industrial and commercial change registration at the Changshou District Branch of the Chongqing Administration for Industry and Commerce, obtained the "Business License of Enterprise Legal Person", with a registered capital of RMB 70,000,000.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chongqing Liangjiang New Area Industrial Development Group Co., Ltd. General Legal Person 7898.27 15.78
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 2397.76 4.79
3 Tianhong Pharmaceutical Innovation Hybrid Securities Investment Fund A Class Fund 593.96 1.19
4 National Social Security Fund 413 Portfolio Social Security Fund 407.43 0.81
5 Hua'an Juyou Jingxuan Hybrid Securities Investment Fund Fund 377.75 0.75
6 Southern China Securities 1000 ETF Fund 299.75 0.60
7 Changsheng Transformation and Upgrading Theme Flexible Allocation Hybrid Securities Investment Fund Fund 33.41 0.07
8 Fuanda Pharmaceutical Innovation Hybrid Securities Investment Fund Fund 19.79 0.04
9 GF Hengxiang Bond Securities Investment Fund A Class Fund 12.56 0.03
10 Morgan Stanley Youyue Anhe Hybrid Securities Investment Fund A Class Fund 8.75 0.02

5. Concept Sectors

  • Immunotherapy
  • CXO Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • Overseas Business
  • Chuangye 300 Index
  • Chuangkeji Index
  • Chuangyiyao Index
  • Chuangye 200 Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information